3,276 followers
RT @GavinGiovannoni: How many MSers will choose alemtuzumab once cladribine and ocrelizumab are amongst the offerings? https://t.co/Qzi0zF7…
RT @GavinGiovannoni: How many MSers will choose alemtuzumab once cladribine and ocrelizumab are amongst the offerings? https://t.co/Qzi0zF7…
Understanding the positive benefit:risk profile of alemtuzumab in relapsing MS https://t.co/ULV0ykLEfI
RT @OhioHealthMS: Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis https://t.co/ViNdakxBkz
RT @GavinGiovannoni: How many MSers will choose alemtuzumab once cladribine and ocrelizumab are amongst the offerings? https://t.co/Qzi0zF7…